Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ATULYA A DEODHAR

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1558376053
CMS profile
24910
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$75,637.02

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $40,590.46 27
Novartis Pharmaceuticals Corporation $11,948.96 11
Eli Lilly and Company $11,515.60 7
UCB SA $5,097.60 2
E.R. Squibb & Sons, L.L.C. $4,550.00 1
Cipla USA Inc. $1,500.00 1
Aurinia Pharma U.S., Inc. $187.17 1
GENZYME CORPORATION $120.53 1
PFIZER INC. $96.75 1
Janssen Biotech, Inc. $29.95 1

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ATULYA A DEODHAR

NPI 1558376053 · CMS profile ID 24910

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ATULYA A DEODHAR, NPI 1558376053, CMS profile ID 24910. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ATULYA A DEODHAR, NPI 1558376053, CMS profile ID 24910. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ATULYA A DEODHAR, NPI 1558376053, CMS profile ID 24910, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $75,637.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $120.5302/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139568601 CMS
Novartis Pharmaceuticals Corporation $9.7402/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086916919 CMS
E.R. Squibb & Sons, L.L.C. $4,550.0001/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101316310 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $174,204.40 143
PY2020 $120,368.60 38
PY2021 $91,311.27 34
PY2022 $61,194.00 31
PY2023 $84,941.13 64
PY2024 $75,637.02 53
PY2025 $86,055.36 55

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,228.33 1
PY2025 Principal investigator $257,699.41 36
PY2024 Recipient $5,907.18 3
PY2024 Principal investigator $344,277.14 11
PY2023 Recipient $39,848.44 13
PY2023 Principal investigator $648,728.30 14
PY2022 Recipient $48,484.00 16
PY2022 Principal investigator $257,694.66 14
PY2021 Recipient $30,120.85 20
PY2021 Principal investigator $251,859.58 24
PY2020 Recipient $60,189.81 46
PY2020 Principal investigator $387,756.92 21
PY2019 Recipient $14,984.68 10
PY2019 Principal investigator $457,357.00 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,200.00 11/06/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175434766
Principal investigator 1 Novartis Pharmaceuticals Corporation $731.19 10/27/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract No dispute reported 06/30/2026 1190297429
Recipient Novartis Pharmaceuticals Corporation $7,228.33 10/16/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190293785
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,515.66 10/01/2025 Non-covered Recipient Entity
OREGON HEALTH SCIENCES UNIVERSITY
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut No dispute reported 06/30/2026 1190312599
Principal investigator 1 UCB SA $2,582.00 09/26/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657940
Principal investigator 1 UCB SA $2,582.00 09/26/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657942
Principal investigator 1 UCB SA $1,719.00 09/26/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657944
Principal investigator 1 UCB SA $500.00 09/24/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246656722
Principal investigator 1 UCB SA $276.00 09/24/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246656724
Principal investigator 1 UCB SA $276.00 09/24/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246656727
Principal investigator 1 UCB SA $276.00 09/24/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246656731
Principal investigator 1 Janssen Research & Development, LLC $1,328.00 09/08/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175435120
Principal investigator 1 UCB SA $5,883.80 08/28/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658688
Principal investigator 1 UCB SA $276.00 06/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658600
Principal investigator 1 UCB SA $2,252.00 06/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658602
Principal investigator 1 UCB SA $276.00 06/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658612
Principal investigator 1 UCB SA $276.00 06/16/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658614
Principal investigator 1 Janssen Research & Development, LLC $6,108.50 05/22/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175435267
Principal investigator 1 Novartis Pharmaceuticals Corporation $47,040.00 05/22/2025 Non-covered Recipient Entity
OHSU APHERESIS COLLECTION UNIT
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) No dispute reported 06/30/2026 1190299289
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,145.70 05/01/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) No dispute reported 06/30/2026 1190296673
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,330.00 04/24/2025 Non-covered Recipient Entity
OHSU APHERESIS COLLECTION UNIT
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut No dispute reported 06/30/2026 1190299298
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,377.53 04/23/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract No dispute reported 06/30/2026 1190296677
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,040.00 03/11/2025 Non-covered Recipient Entity
OHSU APHERESIS COLLECTION UNIT
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract No dispute reported 06/30/2026 1190299292
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $20,570.33 01/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1236000440
Principal investigator 1 Novartis Pharmaceuticals Corporation $431.42 01/21/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) No dispute reported 06/30/2026 1190297425
Principal investigator 1 UCB SA $1,461.00 01/20/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658272
Principal investigator 1 Janssen Research & Development, LLC $4,744.00 01/17/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175435069
Principal investigator 1 UCB SA $276.00 01/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658318
Principal investigator 1 UCB SA $20,506.40 01/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658320
Principal investigator 1 UCB SA $276.00 01/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658322
Principal investigator 1 UCB SA $276.00 01/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658324
Principal investigator 1 UCB SA $276.00 01/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658326
Principal investigator 1 UCB SA $766.60 01/09/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246658328
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,947.00 01/07/2025 Non-covered Recipient Entity
OHSU APHERESIS COLLECTION UNIT
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190299218
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,305.25 01/01/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) No dispute reported 06/30/2026 1190295581
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,001.20 01/01/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract No dispute reported 06/30/2026 1190295585
Principal investigator 1 Novartis Pharmaceuticals Corporation $870.83 01/01/2025 Covered Recipient Teaching Hospital
Ohsu Hospital And Clinics
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut No dispute reported 06/30/2026 1190295590